TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06091462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Interactive Therapeutic Dementia Patient Education Program
Description: Virtual reality is an interactive three-dimensional environment where computer simulation-based fictions and the real and virtual worlds are combined.~Within the scope of this training, in the content of the module on the subject of Dementia; dementia definition, risk factors, signs and symptoms, complications, treatment and nursing care and patient and/or caregiver education. exists. After applying the dementia module, students complete the program by switching to a virtual reality-based simulation program for dementia.
Study: NCT05561062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 80mg
Description: Atorvastatin is one of the most effective drugs used to reduce intracellular cholesterol synthesis. it exerts numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of its basic lipid-lowering properties
Study: NCT06364241

Intervention type: OTHER
Intervention: Focus group
Description: During the focus group, the investigators will explore the cognitive deficits that people with lived experience with psychosis and their carers consider to be the most impairing.

Intervention type: OTHER
Intervention: Focus group
Description: During the focus group, the investigators will explore the cognitive deficits that people with lived experience with psychosis and their carers consider to be the most impairing.
Study: NCT04684082

Intervention type: DEVICE
Intervention: Colonic irrigation with the Colon Hydromat
Description: A designated health professional will administer to the patient the colonic irrigation procedure - using the Colon Hydromat device, a CE certified device for colonic irrigation and cleansing before endoscopic procedures.
Study: NCT05915728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoquatrane (BAY1747846)
Description: 0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteridol
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT06146790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular treatment
Description: For the subjects randomized to endovascular treatment (EVT) treatment initiation is defined as the date and time of arterial puncture. Ideally, femoral artery puncture will occur within 30 minutes of randomization and no longer than 60 minutes after the completion of the qualifying imaging. Treatment initiation (arterial puncture) must occur before 24 hours since the subject was last known well.Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two (2) hours of arterial access. If an appropriate thrombus or residual stenosis is identified, the choice of EVT strategy will be made by the treating neurointerventionalist. All mechanical thrombectomy devices for EVT, which are approved by CFDA for this purpose, are allowed in the trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical management
Description: Standard medical management
Study: NCT05335005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2060
Description: MK-2060 administered via IV infusion
Study: NCT05329649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX001
Description: Administered by intravenous infusion following myeloablative conditioning with busulfan.
Study: NCT05284006

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging, gait analysis, growth, joint test, hearing test, questionnaire, etc.
Description: This study includes 15 major assessments: clinical assessment procedures; anthropometric measurements; activity of daily living and quality-of-life questionnaires; gait kinematics and kinetics analysis; pulmonary function tests (PFT); skeletal radiographs and dual-energy x-ray absorptiometry (DXA); MRI in cervical spine, temporal bones, and hip; computed tomography angiography (CTA) for tracheal obstruction; CT for temporal bones; anesthetic encounters; joint mobility; hearing function; biochemical analyses; and pathological analyses.
Study: NCT03170947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Insoles
Description: Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized insoles
Description: Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
Study: NCT05736445

Intervention type: BEHAVIORAL
Intervention: Wellness coaching plus app use
Description: Participants will participate in wellness coaching and interact with apps on their smartphones
Study: NCT04767802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTG-300
Description: Hepcidin mimetic
Study: NCT04885114

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intraparenchymal rAAV1 - (mi)RNA HTT
Description: Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intraparenchymal rAAV1 - (mi)RNA HTT
Description: Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intraparenchymal rAAV1 - (mi)RNA HTT
Description: Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Intraparenchymal rAAV1 - (mi)RNA HTT
Description: Single dose MRI guided intraparenchymal infusion of rAAV1 - (mi)RNA HTT.
Study: NCT05050734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics - Enhanced (CBIT-E)
Description: Behavioral treatment for persistent tic disorders.
Study: NCT04901351

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Smear
Description: In addition to the routine gynecological follow-up including a cervico-vaginal smear and an HPV test (HPV-HR genome detection), the doctor will propose prospectively to all consecutive patients who meet the inclusion criteria, during a follow-up consultation (post treatment of cervical dysplasia), to participate in the study, that is to have 2 other anal and ENT samples for an HPV test
Study: NCT06142877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Use Reduction
Description: Participants will be incentivized to reduce their social media use by a pre-specified percentage from baseline.
Study: NCT05290610

Intervention type: OTHER
Group type: OTHER
Intervention: Functional mapping
Description: Intracranial EEG data acquisition, observation and behavioral testing, and intracranial electrical stimulation
Study: NCT05844930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Triamcinolone 20 mg (1cc)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActiveMatrix
Description: 1cc ActiveMatrix (Skye Biologics, Inc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 10 mg/mL (5cc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine 10 mg/mL (5cc)
Study: NCT04922996

Intervention type: DRUG
Intervention: Calcium Dobesilate
Description: Dosage of calcium dobesilate in different tissues

Intervention type: DRUG
Intervention: Calcium Dobesilate
Description: Dosage of calcium dobesilate in different tissues
Study: NCT05969821

Intervention type: OTHER
Intervention: observational cohort study
Description: observational cohort study
Study: NCT06041958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: 2 times/week for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse electromagnetic field therapy
Description: 2 times/week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: 2 times/week for 12 weeks
Study: NCT06058390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.
Study: NCT05912478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videogame-Based Therapy
Description: The Nintendo Switch (Version 2) will be used to play video games. Within the scope of the study, Nintendo Switch games were analyzed with respect to their technical and fictional characteristics, required and optional movement patterns, difficulty levels, transitions between difficulty levels, and compatibility with priority problems. The selected activities will prioritize the activation of the scapular muscles. Throughout the activities, the participant will be required to mimic the on-screen avatar's movements. The player will receive a higher score if his or her movements in the game resemble the avatar's in terms of angular, velocity, and fluidity.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: The participants who were placed on a waiting list for eight weeks and constituted the control group will be asked to carry on with their normal activities. Participants in the control group will be contacted by phone in the fourth week to inquire about their status and to remind them that the exercise program will begin in the coming weeks. At the end of the 8-week study, the participants from the control group will participate in the exercise program.
Study: NCT04541108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilvegostomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabestomig
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT05627310

Intervention type: OTHER
Intervention: Diagnostic
Description: Training dataset was used to train the deep learning model, which was validated and tested by external dataset.

Intervention type: OTHER
Intervention: Diagnostic
Description: Training dataset was used to train the deep learning model, which was validated and tested by external dataset.
Study: NCT04782895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Description: Three doses administered intramuscularly at 0, 45 day and 6 month.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil®9
Description: Three doses administered intramuscularly at 0, 45 day and 6 month.
Study: NCT06457412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group for the treatment of childhood obesity
Description: Intervention for children aged 6 to 12 years with childhood obesity (with a BMI greater than the 99th percentile), fostering motivation and encouraging changes toward healthy lifestyle habits to achieve greater adherence and to improve health. The program comprises 9 educational sessions designed by specialized professionals (code of Spanish register: 2007144741729) to be conducted in a health center. The sessions will be held every 15 days, with a duration of 90 minutes for a group of 10 children and another group of 10 family members and/or caregivers. Professionals from different disciplines (paediatricians, psychologists, nurses and nutritionists), will meet with groups of pediatric patients and in another group with their family members or primary caregivers.
Study: NCT05168605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit
Description: Patients receiving home Visits
Study: NCT05102123

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytisine
Description: Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Listed as a natural health product in Canada, cytisine is utilized to aid in smoking cessation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Messaging
Description: Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Video Messaging
Description: Supportive messaging utilizing a video messaging platform to encourage patients to abstain from smoking throughout the treatment period.
Study: NCT05962320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and counselling
Description: Education and counselling of patients and their parents

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoiding the use of nasogastric catheters, drains and urinary catheters
Description: Avoiding the use of nasogastric catheters, drains and urinary catheters or/and removing them as early as possible

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation of intestinal motility in the postoperative period
Description: Stimulation of intestinal motility in the postoperative period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initiation of oral intake in the early postoperative period
Description: Initiation of oral intake in the early postoperative period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early removal of the patient by reducing postoperative IV fluid infusion
Description: Early removal of the patient by reducing postoperative IV fluid infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Initiation of early mobilization of the patient in the postoperative period
Description: Initiation of early mobilization of the patient in the postoperative period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reducing opioid use and ensuring pain management
Description: Reducing opioid use and ensuring pain management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implement nausea and vomiting prophylaxis
Description: Implement nausea and vomiting prophylaxis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of thirsty
Description: Management of thirsty

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Management of fear and stress
Description: Use of recommended non-pharmacological interventions in the management of fear and stress
Study: NCT05801458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modeling Resin Insertion Technique
Description: One drop of modeling resin will be dispensed into a clean mixing well. Following the placement of the resin composite into the prepared site, a composite instrument (round-ended plugger with a diameter of 2 mm) will be dipped into the modeling resin. With modeling resin on the instrument, the resin composite is sculpted and manipulated to the desired shape. This will be repeated with each increment. Each increment will be polymerized for 20 sec with a LED light-curing unit.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional resin composite Incremental Placement Technique
Description: A three-step etch-and-rinse adhesive system will be used according to the manufacturer's instructions. 37.5% phosphoric acid (Kerr Co, Orange, CA, USA) will be applied to the enamel and dentin for a period of 30 s and 15 s, respectively. Subsequently the cavities will then be rinsed with an air/water spray for 15 s. A layer of primer will be applied to the dentin for 30 sec, afterward gentle air-drying for 5 sec. Then, the bond (AdheSE adhesive) will be applied on the enamel and dentin and light cured with a LED curing unit for about 30 sec. Tetric N-Ceram will then be applied using an incremental filling technique, each increment will not exceed 2mm in thickness. Each increment will be polymerized for 20 sec with a LED light-curing unit.
Study: NCT05529784

Intervention type: DRUG
Intervention: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: Dupilumab 300mg in pre-filled injector Q2W
Study: NCT06625190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi CliniMACS Prodigy ® system
Description: Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺/β T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: All subjects will receive zoledronic acid intravenously on days +28, +56, +84, +112, and +140.~Dosing in the phase Ib portion of the study will follow a 3 + 3 design where the first 3 subjects will receive the expected phase II dose of 1.25 mg/m2 (dose level 1). If no dose-limiting toxicities (DLTs) occur in these subjects, dose level 1 will be the maximum tolerated dose. However, if at least 1 DLT is observed in the first 3 patients, 3 additional subjects will be enrolled at dose level 1. If more than 2 DLTs are observed in these 6 subjects, then dose de-escalation to 0.8 mg/m2 (dose level 0) will occur and 3-6 additional subjects may be enrolled.~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase Ib portion.
Study: NCT06626100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-themed game
Description: The intervention includes three parts: quiz questions on knowledge on and benefits of exercise; monitored step count using smartphone tracker; whatsapp reminders on the benefits of exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet-themed game
Description: The intervention includes two parts: quiz questions on knowledge on and benefits of healthy diet; whatsapp reminders on the benefits of healthy diet.
Study: NCT05330416

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group Reference Strategy
Description: Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration and drainage with a seton.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Test Strategy
Description: Patients undergoing surgery for anoperineal suppuration in the context of Crohn's disease with detailed examination of the suppuration without drainage via a seton.
Study: NCT05056701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: annual follow-up during 10 years
Description: an annual follow-up is carried out systematically for a total of 10 years in order to detect the subsequent occurrence of CKD
Study: NCT06088355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HV-PDAE: High Volume Partnered Dance Aerobic Exercise
Description: HV-PDAE classes will meet 5 times a week for 90 minute sessions for 3 weeks at onset of trial and then every 4 weeks for a year. All participants will receive 112.5h of training. PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MV-PDAE: Moderate Volume Partnered Dance Aerobic Exercise
Description: MV-PDAE: MV classes will meet biweekly for 52 weeks for 65-minute sessions. All participants will receive 112.5h of training. . PDAE was adapted for older adults with balance impairments; modifications were made to the frame and steps of Argentine tango. People with PD partner an individual without PD, e.g., staff, caregiver, friend, or university student. The instructor, staff lead and assistants monitor participants for safety. Class sizes will consist of 6 or fewer pairs of participants with PD and partners. Participants with PD will dance with new partners (individuals without PD) every 15-20 minutes. Participants will learn new steps in each class. The class format includes practicing steps, warm-up, partnering and rhythmic exercises, learning new steps, combining old and new steps, cool down. PDAE classes follow a syllabus with new steps, rhythms and embellishments included in each class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MV-WALK: Moderate Volume Walking
Description: MV-WALK (65-minute sessions): WALK will control for the walking that participants in PDAE do and will also take place in groups to control social effects of intervention. Walking for
Study: NCT05204316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Analysis of Speech
Description: Recordings will be transcribed manually to written digital text formats, on which NLP tools such as tokenisation and lexical analysis will be performed.